Dr. Weiwei Xiao has been working in Sun Yat-Sen University Cancer Center since she obtained Doctor's degree in 2011. She is currently an associate professor in the Department of Radiation Oncology. Her work focused on radiotherapy and research of gastrointestinal cancer, including rectal cancer, colon cancer, and anal cancer, etc. Her experience and data of anus-preserving comprehensive treatment of low rectal cancer have been included in international journals. She also presided over a number of funds such as the National Natural Science Foundation of China and the Natural Science Foundation of Guangdong Province. She has published more than 40 High-level Papers.

Clinical and basic research on radiation oncology of colorectal cancer and anal cancer.

1) Mei Y#, Xiao W#, Hu H#, Lu G#, Chen L#, Sun Z, Lü M, Ma W, Jiang T, Gao Y, Li L, Chen G, Wang Z, Li H, Wu D*, Zhou P*, Leng Q*, Jia G*.Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer. Clin Transl Med. 2021 Jun;11(6)

2) Guo ZW#, Xiao WW#, Yang XX#, Yang X, Cai GX, Wang XJ, Han BW, Li K, Zhai XM, Li FX, Huang LM, Wu YS*, Gao YH*. Noninvasive prediction of response to cancer therapy using promoter profiling of circulating cell-free DNA. Clin Transl Med. 2020 Sep;10(5)

3) Fu L#, Li S#, Xiao W#, Yu K, Li S, Yuan S, Shen J, Dong X, Fang Z, Zhang J, Chen S, Li W, You H, Xia X, Kang T, Tan J, Chen G, Yang AK*, Gao Y*, Zhou P*. DGKA Mediates Resistance to PD-1 Blockade. Cancer Immunol Res. 2021 Apr;9(4)

4) Xiao WW#, Li M#, Guo ZW#, Zhang R, Xi SY, Zhang XG, Li Y, Wu DQ, Ren YF, Pang XL, Wan XB, Li K, Zhou CL, Zhai XM, Liang ZK, Wang QX, Zeng ZF, Zhang HZ, Yang XX, Wu YS, Li M*, Gao YH*. A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2)

5) Liu S#, Jiang T#, Xiao L#, Yang S, Liu Q, Gao Y, Chen G*, Xiao W*. Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer:a systematic review and meta-analysis.The Oncologist. 2021 Sep;26(9)

6) Zhang S#, Zhang R#, Li RZ, Wang QX, Chang H, Ding PR, Li LR, Wu XJ, Chen G, Zeng ZF, Xiao WW*, Gao YH*. Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer. Cancer Sci. 2021 Jun 19;112(9)

7) Zhang S, Wang Q, Zhou C, Chen K, Chang H, Xiao W*, Gao Y*. Colorectal cancer, radiotherapy and gut microbiota. Chin J Cancer Res. 2019 Feb;31(1)

8) Zhou C#, Xiao W#, Jiang T#, Guo Z, Li M, Chang H, Wu Y, Chen M, Shi M*, Xu W*, Gao Y*. Targeting SGK1 enhances the efficacy of radiotherapy in locally advanced rectal cancer. Biomed Pharmacother. 2020 May;125(2020)

9) Zhou C#, Jiang T#, Li R#, Yuan Y, Xie W, Huang X, Wang Q, Chang H, Chen G, Li Y, Zeng Z, Xiao W*, Gao Y*. Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. Cancer Commun (Lond). 2021 Sep;41(9)

10) Yuan Y#, Xiao WW#, Xie WH#, Cai PQ, Wang QX, Chang H, Chen BQ, Zhou WH, Zeng ZF, Wu XJ, Liu Q, Li LR, Zhang R*, Gao YH*. Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection. BMC Cancer. 2021 Feb 19;21(1) 

Updated November 2021 by International Office, Sun Yat-sen University Cancer Center